Form S-1 Eloxx Pharmaceuticals Inc For: 7 May
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eloxx Pharmaceuticals Inc (ELOX)
The Eloxx Pharma share price today is 0.340, view OTC ELOX stock exchange data. Track the latest Eloxx Pharma share price with real-time updates on ELOX stock performance including market cap, day range, 52-week range and dividend yield. Access ELOX charts, earnings dates and analyst estimates to support your investment decisions.
OTC Markets
Currency in USD
0.340
-0.209(-38.07%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.200
0.600
52 wk Range
0.002
0.600
Unusual trading volume
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.2000.600
52 wk Range
0.0020.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ELOX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Form 13G Eloxx Pharmaceuticals For: 1 May
- Investing.com
- Form S-1 Eloxx Pharmaceuticals Inc For: 7 May
- Investing.com
- Form 13G Eloxx Pharmaceuticals For: 1 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Earnings
Latest Release
05-05-2026
EPS / Forecast
-0.08 / --
Revenue / Forecast
-- / --
Compare ELOX to Peers and Sector
Metrics to compare | ELOX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELOXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −0.1x | −0.5x | |
PEG Ratio | - | 0.01 | 0.00 | |
Price/Book | −0.5x | 1.5x | 2.6x | |
Price / LTM Sales | - | 6.6x | 3.1x | |
Upside (Analyst Target) | - | 699.8% | 53.0% | |
Fair Value Upside | Unlock | 39.5% | 6.3% | Unlock |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
FAQ
What Is the Eloxx Pharma (ELOX) Share Price Today?
The Eloxx Pharma share price today is 0.340.
What is the current Eloxx Pharma (ELOX) share price and day range?
As of 22-05-2026, the Eloxx Pharma share price is 0.340, with a previous close of 0.549. The share price has ranged from 0.200 to 0.600 today, while the 52-week range spans from 0.002 to 0.600.
What Is the Eloxx Pharma Market Cap?
As of today, Eloxx Pharma market cap is 2.580M.
What Is Eloxx Pharma's Earnings Per Share (TTM)?
The Eloxx Pharma EPS (TTM) is -0.343.
From a Technical Analysis Perspective, Is ELOX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Eloxx Pharma Trade On?
Eloxx Pharma is listed and trades on the OTC Markets.
What Is the Stock Symbol for Eloxx Pharma?
The stock symbol for Eloxx Pharma is "ELOX."
How Many Times Has Eloxx Pharma Stock Split?
Eloxx Pharma has split 3 times.
How Many Employees Does Eloxx Pharma Have?
Eloxx Pharma has 10 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.